![]() ![]() Super Doctors is an independent publisher that has developed its own selection methodology itis not affiliated with any federal, state or regulatory body. No representation is made that the quality of the medical services provided by the physicians listed in this Web site will be greater than that of other licensed physicians and past results do not guarantee future success. It is not a title or moniker conferred upon individuals. Super Doctors is the name of a publication. Selecting a physician is an important decision it should not be based solely on advertising or listings. We strive to maintain a high degree of accuracy in the information provided, but make no claim, promise or guarantee about the accuracy, or adequacy of the information contained in, or linked to or its associated Web sites. All rights reserved.ĭisclaimer: Information in this Web site is not medical advice, nor is Super Doctors a physician referral service. © 2023 Super Doctors ®, Key Enterprises LLC. Home | About | Selection Process | Advertising | Contact | Physician FAQ | Advanced Search | Browse Listings For more information, call (310) 854-6201, or go to. In addition to its clinical services, Retina-Vitreous Associates provides continuing education and consulting services to the local, national and international ophthalmic communities and other healthcare industries. The physicians at Retina-Vitreous Associates are nationally recognized leaders in their field and participate in most clinical trials assessing new therapies for macular degeneration, diabetic retinopathy, as well as other retinal diseases. Retina-Vitreous Associates Medical Group specializes in the treatment of diseases affecting the retina, the vitreous and the macula. "This is a huge advance to treat such a sight debilitating disorder and one we're proud to be a part of." Boyer, MD, Senior Partner, Retina-Vitreous Associates Medical Group. "We are extremely pleased to offer our patients a non-surgical option to treat VMA," said David S. The breakdown of these proteins allows a better separation between the vitreous and macula and can reduce the chances that tugging will occur. JETREA is an enzyme that breaks down proteins in the eye responsible for VMA. ![]() The medication is injected into the patient's affected eye once as a single dose. ![]() The only other option to treat VMA is surgery, which is often reserved for patients at a time when possible irreversible damage is already done. Food and Drug Administration (FDA), approved JETREA as the first pharmacological agent for the treatment of VMA and became available to patients this week. This movement can lead to damage of the macula due to pulling or tugging on the macula. VMA can contribute to eye problems if the vitreous (jelly in the center of the eye) starts to move away from the macula (a part of the retina responsible for reading vision). Over a 1/4 million people in the US are affected by VMA a progressive, sight-threatening condition that, when left untreated, frequently leads to retinal distortion, further deterioration in vision, and irreversible damage to eyesight. 5, 2013 (GLOBE NEWSWIRE) - Retina-Vitreous Associates Medical Group, nationally recognized leaders that specialize in the treatment of diseases affecting the retina, are the first on the West Coast to offer their patients the much anticipated, JETREA, a new non-surgical treatment option for patients with Symptomatic Vitreomacular Adhesion (VMA), a retinal disorder that affects central vision. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |